Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis.
It is currently agreed that stone formation in the urinary tract requires supersaturation with respect to a given solid phase. However, this principle fully applies only to stones other than calcium-containing stones, in which case compounds acting as inhibitors are postulated to naturally occur in urine. Stone formation would therefore ensue from an imbalance between promoters and inhibitors. The saturation state can be estimated by means of computer model systems based on ab initio calculations, which account for the main soluble complexes formed in urine between relevant cations and anions. This estimates the overall promoting potential of urine. However, in the case of calcium nephrolithiasis, supersaturation does not make a clear-cut separation between normal subjects and patients. Several studies in the last two decades have identified many inhibitors of calcium oxalate and calcium phosphate crystallization, which are classified into the ionic and macromolecular. They have been shown to act on kinetics by interfering with nucleation, growth and aggregation of crystals. Unfortunately, except for citrate, none of the newly discovered substances has been definitely characterized in its molecular composition and structure, type and potency of inhibition, differences in concentration and structure between stone-forming and non stone-forming subjects. Citrate exhibits a dual action in urine, opposing crystal formation by both thermodynamic and kinetic mechanisms. At present it is the only natural inhibitor which can be measured in urine, quantitated as to inhibitory activity and used in medical treatment.
Marangella
Martino
M
Division of Nephrology, Dialysis and Renal Stone Centre, Mauriziano Hospital, Torino, Italy. mmarangella@mauriziano.it
Bagnis
Cristiana
C
Bruno
Michele
M
Vitale
Corrado
C
Petrarulo
Michele
M
Ramello
Adriano
A
D002129:Calcium Oxalate / Q000737:chemistry; D016022:Case-Control Studies; D002951:Citrates / Q000737:chemistry; D003460:Crystallization; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D012680:Sensitivity and Specificity; D016482:Urinalysis; D014545:Urinary Calculi / Q000737:chemistry* / Q000188:drug therapy*
D002951:Citrates; D002129:Calcium Oxalate